Skip to main content
. 2015 Mar 31;10(3):e0121707. doi: 10.1371/journal.pone.0121707

Fig 8. EMT markers show loss of expression by immunohistochemistry in tumors when compared to their corresponding wild type RG cell lines.

Fig 8

TJP1 A- Diffuse membrane expression in wild type RG cells, B- Multifocal loss of expression in tumors, C- Loss of expression around necrotic areas (LCAS-R—12 weeks post-injection) (40X, inserts digital magnification 4X); TJP3 D- 2/3 of cells present cytoplasmic expression in wild type RG cells; E- Extensive areas of loss of expression in tumors (LCAS-R—12 weeks post-injection), F- Loss of expression in areas surrounding necrosis (LC26-R—12 weeks post-injection) (40X, inserts digital magnification 4X); β-catenin G- Diffuse membrane expression in wild type RG cells, H- Almost complete loss of expression in corresponding tumors (LCAS-R—12 weeks post-injection), I- Loss of expression in areas surrounding necrosis (LC26-R—12 weeks post-injection) (40X, inserts digital magnification 4X); N-cadherin, J- Low membrane expression in wild type RG cells, K- Extensive membrane expression in tumor cells (LCAS-R—12 weeks post-injection) (40X, inserts digital magnification 4X), L- Extensive membrane expression in the areas surrounding necrosis (LC26-R—12 weeks post-injection) (40X, inserts digital magnification 4X). N—Necrosis.